Register for our S/EIS Fund

The area where biotech meets deep tech is an area that has not only attracted the attention of traditional biotech funds but also hardened deep tech funds that historically were scared off by the word biotech let alone drug discovery!

In the 5th episode of o2h ChaiTime we discussed the powerful role of Artificial Intelligence and Machine Learning in transforming the speed and cost of innovative drug discovery as well as the evolution of the business models, collaborating with pharma, creating a large data-set, the funding landscape and more.

The panelists
Jackie Hunter Director at BenevolentAI

Jackie is currently Chief Executive Officer of Benevolent Bio and Director of BenevolentAI, a company that uses AI to augment the research capabilities of drug scientists, radically changing the way R&D is done.

Hannah Sore CEO at Pharmenable

Dr. Hannah Sore co-founded PharmEnable, a Cambridge-based (UK) drug discovery spin-out using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate molecules.

Tina Larson President and COO at Recursion Pharma

Tina has more than 20 years of experience in the biopharmaceutical industry, most of it in the San Francisco Bay Area at Genentech. Before joining Recursion she was Senior Vice President and Executive Committee member at Achaogen.

Dr. Jerome Wicker Cheminformatician at Oxford Drug Design

Jerome obtained his chemistry master’s degree at Worcester College, Oxford, where he completed his D.Phil. studying molecular flexibility and its impact on crystal formation.

Sunil Shah CEO at o2h Ventures

Sunil Shah is a serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.

Register for Invitations